Towards a Shared Language: Defining endocrine-immune-related adverse events
On behalf of the Endocrine Society’s Oncoendocrinology Special Interest Group, Ling Zhu, MBBChir, discusses her recent paper that addressed “the gap in standardized nomenclature, clinical, laboratory and radiological evaluations, and management principles of endocrine- immune-related adverse events (E-irAEs).” She also talks to corresponding author, Afreen Shariff, MD, about the need for nomenclat
November 13, 2025